Deterioration of memory, attention, and decreased performance are also associated with impaired cerebral circulation. To improve blood circulation, doctors prescribe drugs with antioxidant properties. One of the most inexpensive means is Mexiprim. This is an effective drug, affordable and gives results in the first weeks.
Compound
There are two main forms of release of this drug - injections and tablets, the composition of which differs from each other in the amount of ethylmethylhydroxypyridine succinate .
One milliliter of Mexiprim solution contains 50 grams of the active drug compound, as well as about 1 milliliter of an excipient - water for injection.
One film-coated Mexiprim tablet contains 0.125 grams of ethylmethylhydroxypyridine succinate , as well as excipients such as talc, kaolin, povidone, sodium carboxymethyl starch, calcium stearate and MCC.
The shell of the tablet form of the drug contains compounds such as talc, hypromellose, titanium dioxide, and macrogol.
Release form
As mentioned earlier, the drug is produced in the form of round tablets, biconvex in shape and coated with a specialized white or cream-colored coating, as well as in the form of an injection solution, which is a transparent liquid of colorless or pale yellow color.
The nominal weight of one tablet is 125 mg. The tablets are packaged in blisters (cell-shaped made of aluminum foil and PVC) of 10 pcs. in everyone. One cardboard package can contain 1,2,3,4, 6 blisters.
The solution intended for the preparation of injections is packaged in ampoules of 2 or 5 ml. in each and placed in contour cells. One cardboard package may contain 20, 50 or 100 ampoules complete with a special knife for opening them.
Mexiprim tablets: composition and description
The drug is produced in the form of injections for injections and tablets. They contain the active ingredient ethylmethylhydroxypyridine in the form of succinate (0.125 g in each tablet). It also contains additional components - kaolin, talc, calcium stearate and others.
Tablets are produced in standard quantities of 10 pieces (from 1 to 6 per package). The solution for injections is produced in ampoules of 2 or 5 ml. Pharmacies sell packages containing 100 ampoules or 50.
The medicine acts as an antioxidant. The active component destroys free radicals - dangerous molecules that destroy cells. This leads to increased adaptation to situations involving physical or psychological stress. The drug also has the following properties:
- prevention of problems with memory and learning ability;
- lowering cholesterol levels (hypolipidemic properties);
- improved attention;
- prevention of alcohol intoxication;
- increased performance;
- stimulating blood circulation;
- stimulating the connection of platelets with each other;
- anticonvulsant effect;
- improving oxygen supply to cells.
Both tablets and ampoules with solution are stored in cool conditions (temperature up to 20 degrees). Humidity should be moderate, access to sunlight should be excluded. The shelf life is 3 years from the date of production.
Pharmacodynamics and pharmacokinetics
Since this drug belongs to the heteroaromatic antioxidant series , Mexiprim is distinguished by its wide range of applications. The medicine increases the body's resistance to stressful situations. When using the drug, its anxiolytic properties , without muscle relaxant effects or drowsiness .
In addition, the drug reduces and prevents the occurrence of memory and learning disorders , and has a nootropic and anticonvulsant effect on elderly patients. Thanks to its antihypoxic and antioxidant properties, Mexiprim helps improve performance and concentration, and in addition, minimizes the harmful toxic effects of alcoholic beverages.
Mexiprim has a positive effect on brain tissue, as well as the body’s circulatory system by stimulating blood microcirculation and platelet aggregation . The drug reduces cholesterol due to its pronounced lipid-lowering abilities . When the drug enters the human body, it is rapidly metabolized and transformed into glucurone-conjugated breakdown products .
Indications for use of Mexiprim
General indications for use for the two main forms of the drug are the following conditions and diseases:
- vegetative-vascular dystonia;
- withdrawal syndrome accompanied by vegetative-vascular and neurosis-like disorders in alcoholism ;
- nervous disorders;
- cognitive disorders in asthenic and psychoorganic syndrome caused by intoxication , circulatory disorders in the brain, neuroinfections, atrophic or senile processes ;
- exposure to stress ;
- disorders of intelligence and memory in elderly patients.
Mexiprim injection solution is also used for cerebral circulatory (acute forms), for cognitive disorders caused by atherosclerotic genesis , and in addition, for dyscirculatory encephalopathy.
Contraindications
General contraindications for both injections and Mexiprim tablets are:
- pregnancy;
- childhood;
- hypersensitivity;
- lactation period;
- disorders of the liver or kidneys (acute stages of the disease).
The tablet form of the drug is not recommended for use in case of renal or liver failure .
Contraindications and side effects
In some cases, taking the drug is excluded:
- all stages of pregnancy;
- breastfeeding period;
- childhood;
- acute disorders of kidney or liver function.
- chronic liver and kidney diseases.
Side effects, as a rule, occur only as a result of an overdose. They are associated with allergic reactions, a feeling of dry mouth, nausea, insomnia or, conversely, increased drowsiness. If such symptoms occur, you must immediately stop taking the drug and, if necessary, consult a doctor for advice.
Instructions for use of Mexiprim (Method and dosage)
The instructions for use of Mexiprim tablets prescribe taking them orally 2-3 times a day in a dosage individually determined by the doctor, for each individual patient, taking into account all physiological characteristics. It is recommended to start using the drug with a dosage of 0.25-0.5 grams. The maximum average daily dose of the drug should not exceed 0.8 grams.
The duration of the therapeutic course of treatment with the drug, depending on the type and severity of the patient’s disease/condition, can vary from 5 days to 6 weeks. It is recommended to reduce the dosage of the drug gradually over the last 2-3 days of the course of treatment.
Mexiprim injections are administered intramuscularly or intravenously (drip or jet) 1-3 times a day. The dosage of the drug is determined individually, taking into account the characteristics of each specific case. When administering an injection solution by infusion, the drug is diluted with sodium chloride. As a rule, the dosage of the first injections does not exceed 100 mg. Subsequently, the dose of the drug is gradually increased.
The duration of the therapeutic course of treatment with Mexiprim injection solution also depends on the patient’s condition and the severity of the disease; it can last from 7 to 30 days.
Registration number
PN 001916/02
Trade name of the drug
Mexiprim®
INN or group name
Ethylmethylhydroxypyridine succinate.
Dosage form
Film-coated tablets.
Composition of the drug
One tablet contains:
active ingredient: ethylmethylhydroxypyridine succinate 125 mg;
excipients: kaolin, sodium carboxymethyl starch, microcrystalline cellulose, povidone K 17, talc, calcium stearate;
excipients (shell): hypromellose, macrogol, titanium dioxide, talc.
Description
Round biconvex tablets, film-coated, white or almost white. On a cross section, the kernel is white to white with a grayish or yellowish or brownish tint.
Pharmacological group
Antioxidant agent.
ATX code
N07XX.
Pharmacological properties
Pharmacodynamics.
Mexiprim is a 3-hydroxypyridine derivative; has antioxidant, antihypoxic, anti-ischemic, membrane-protective, nootropic, stress-protective, anticonvulsant, anxiolytic, hypolipidemic effects.
The mechanism of action of the drug is due to its antioxidant, antihypoxic and membrane protective effects. Mexiprim reduces the manifestations of oxidative stress, inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, and improves the structure and function of the cell membrane. The drug modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, gamma-aminobutyric acid (GABA), acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, neurotransmitter transport and improve synaptic transmission. Mexiprim increases dopamine levels in the brain. Causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of adenosine triphosphate (ATP) and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes.
The drug has a wide range of pharmacological activity; increases the body's resistance to stress and the effects of various damaging factors in pathological conditions (hypoxia and ischemia, cerebrovascular accident, intoxication with ethanol and antipsychotic drugs).
In conditions of a critical decrease in coronary blood flow, it helps to preserve the structural and functional organization of cardiomyocyte membranes, stimulates the activity of membrane enzymes (phosphodiesterase, adenylate cyclase, acetylcholinesterase). Supports the activation of aerobic glycolysis that develops during acute ischemia and promotes the restoration of mitochondrial redox processes under hypoxic conditions, increases the synthesis of ATP and creatine phosphate. Ensures the integrity of the morphological structures and physiological functions of the ischemic myocardium. Improves the clinical course of myocardial infarction, increases the effectiveness of therapy, reduces the incidence of arrhythmias and intracardiac conduction disorders. Normalizes metabolic processes in ischemic myocardium, increases the antianginal activity of nitrates, improves the rheological properties of blood, reduces the consequences of reperfusion syndrome in acute coronary insufficiency.
Improves the functional state of ischemic myocardium. In conditions of coronary insufficiency, it increases collateral blood supply to the ischemic myocardium, helps maintain the integrity of cardiomyocytes and maintain their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction.
Improves the metabolism of brain tissue and their blood supply, improves microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membrane structures of blood cells (erythrocytes and platelets). It has a lipid-lowering effect, reduces the content of total cholesterol and low-density lipoproteins.
Exhibits an anxiolytic effect, not accompanied by a muscle relaxant effect; has nootropic properties, prevents and reduces learning and memory disorders that occur with aging and exposure to various pathogenic factors; has an anticonvulsant effect; increases concentration and performance.
The anti-stress effect is manifested in the normalization of post-stress behavior, somatovegetative disorders, restoration of sleep-wake cycles, impaired learning and memory processes, reduction of dystrophic and morphological changes in various structures of the brain.
Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.
It has a pronounced antitoxic effect during withdrawal syndrome. Eliminates neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral disorders, autonomic functions, and helps reduce the severity of cognitive impairment caused by long-term use of ethanol. Under the influence of the drug, the effect of tranquilizing, neuroleptic, antidepressant, hypnotics and anticonvulsants is enhanced, which makes it possible to reduce their doses and reduce side effects.
Pharmacokinetics.
Rapidly absorbed when taken orally. The maximum concentration (Cmax) at doses of 400-500 mg is 3.5-4.0 mcg/ml. Quickly distributed in organs and tissues. The average retention time of the drug in the body (MRT) when taken orally is 4.9-5.2 hours. Metabolized in the liver by glucuron conjugation. 5 metabolites have been identified: 3-hydroxypyridine phosphate - formed in the liver, with the participation of alkaline phosphatase, it breaks down into phosphoric acid and 3-hydroxypyridine; 2nd metabolite - pharmacologically active, formed in large quantities and found in urine 1-2 days after administration; 3rd - excreted in large quantities in the urine; 4th and 5th – glucurone conjugates. The half-life (T1/2) when taken orally is 2.0-2.6 hours. It is quickly excreted in the urine, mainly in the form of metabolites and in small quantities unchanged. The most intensive elimination occurs during the first 4 hours after taking the drug. Rates of urinary excretion of unchanged drug and metabolites have individual variability.
Indications for use
- Consequences of acute cerebrovascular accidents, including after transient ischemic attacks, in the subcompensation phase as preventive courses;
- Mild traumatic brain injury, consequences of traumatic brain injury;
- Encephalopathies of various origins (dyscirculatory, dysmetabolic, post-traumatic, mixed);
- Autonomic dystonia syndrome;
- Mild cognitive disorders of atherosclerotic origin;
- Anxiety disorders in neurotic and neurosis-like conditions;
- Coronary heart disease as part of complex therapy;
- Relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders, post-withdrawal disorders;
- Conditions after acute intoxication with antipsychotic drugs;
- Asthenic conditions, as well as for the prevention of the development of somatic diseases under the influence of extreme factors and stress;
- Impact of extreme (stress) factors.
Contraindications
Acute dysfunction of the liver and kidneys, hypersensitivity to the active substance and other components of the drug. Due to insufficient knowledge of the effect of the drug - childhood, pregnancy, breastfeeding.
Directions for use and doses
Inside. 125-250 mg (1-2 tablets) 3 times a day.
The initial dose is 125-250 mg (1-2 tablets) 1-2 times a day with a gradual increase until a therapeutic effect is obtained. The maximum daily dose is 750 mg (6 tablets).
Duration of treatment – 2-6 weeks; to relieve alcohol withdrawal – 5-7 days. The duration of therapy in patients with coronary heart disease is at least 1.5–2 months. Treatment is stopped gradually, reducing the dose over 2-3 days.
Repeated courses (on the recommendation of a doctor) are preferably carried out in the spring and autumn.
Side effect
Rarely - nausea, dry mouth, drowsiness, allergic reactions.
Overdose
Symptoms: sleep disturbance (insomnia, in some cases drowsiness).
Treatment: symptomatic therapy.
Interaction with other drugs
Mexiprim is compatible with all drugs used to treat somatic diseases.
Enhances the effect of benzodiazepine drugs, antidepressants, anxiolytics, antiepileptic drugs (carbamazepine) and antiparkinsonian drugs (levodopa), nitrates. Reduces the toxic effect of ethanol.
Impact on the ability to drive vehicles and machinery
During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Release form
Film-coated tablets, 125 mg. 10 tablets in a blister pack made of polyvinyl chloride film and printed varnished aluminum foil. 1, 2, 3, 4 or 6 blister packs together with instructions for medical use of the medicinal product in a cardboard pack.
Storage conditions
At a temperature not exceeding 30°C in consumer packaging (cardboard pack).
Keep out of the reach of children.
Best before date
5 years. Do not use after the expiration date indicated on the package.
Vacation conditions
Dispensed by prescription.
, Russia 249036, Kaluga region, Obninsk, st. Koroleva, 4 Tel./fax: (48439) 6-47-41 Address of production place Kaluga region, Obninsk, Kyiv highway, building. 103, building 107
Marketing authorization holder/organization receiving consumer complaints
JSC "Nizhpharm", Russia 603950, Nizhny Novgorod, st. Salganskaya, 7 Tel., fax E-mail
Mexiprim's analogs
Level 4 ATC code matches:
Trigamma
Riluzole
Huato Boluses
Vitagamma
Vitaxon
Hypoxene
Glycine
Mexidol
Neurox
Glitsed
Cytoflavin
Among the analogues of Mexiprim, the following drugs can be distinguished: Medomexi, 2-ethyl-6-methyl-3-hydroxypyridine succinate, Armadin, 3-hydroxy-6-methyl-2-ethylpyridine succinate, Mexidant, Mexicor, Meksifin, Mexidol, Metostabil, Cerecard , Mexipridol and Ethylmethylhydroxypyridine succinate.
It is worth noting that quite often patients have the question of what is better: Mexiprim or Mexidol ? An unambiguous answer to this question can only be given by the attending physician, who, after a comprehensive medical examination, can correctly prescribe this or that drug, taking into account all the characteristics of a particular patient.
Mexiprim price, where to buy
The average price of Mexiprim tablets varies from 140 to 170 rubles.
The price of Mexiprim in ampoules averages 300-330 rubles.
- Online pharmacies in RussiaRussia
- Online pharmacies in UkraineUkraine
ZdravCity
- Mexiprim tablets p.p.o.
125 mg 30 pcs. ZAO OKFK 159 rub. order - Mexiprim solution for intravenous and intramuscular injection. 50mg/ml 5ml 5 pcs. LLC NTFF POLYSAN
RUB 315 order
- Mexiprim tablets p.p.o. 125 mg 60 pcs. ZAO OKFK
RUB 306 order
- Mexiprim solution for intravenous and intramuscular injection. 50mg/ml 5ml 15 pcs. LLC NTFF POLYSAN
RUR 981 order
Pharmacy Dialogue
- Mexiprim (tablet p/o 125 mg No. 60) Obninsk Chemical-Pharmaceutical
RUB 356 order
- Mexiprim (amp. 50 mg/ml 5 ml No. 5) Polisan NTFF
340 rub. order
- Mexiprim (amp. 50 mg/ml 2 ml No. 10) Moscow Endocrine Plant
RUB 342 order
- Mexiprim (amp. 50 mg/ml 2 ml No. 10) Polisan NTFF
RUB 331 order
- Mexiprim (tab.p/vol. 125 mg No. 30) Obninsk Chemical-Pharmaceutical
RUB 158 order
show more
Pharmacy24
- Mexiprim 125 mg No. 30 tablets ZAT "OHFK", Russia
130 UAH. order - Mexiprim 50 mg/ml 2 ml No. 10 injection solution TOV "NTFF" Polisan", Russian Federation
348 UAH order
Buy Mexiprim solution intravenously and intramuscularly 50 mg/ml 2 ml No. 10 in pharmacies
Instructions for use Mexiprim Buy at the pharmacy Mexiprim solution IV and IM 50 mg/ml 2 ml No. 10 Dosage forms solution for injection 50 mg/ml 2 ml Synonyms Medomexi Mexidant Mexidol Mexicor Mexico Neurox Cerecard Group Antioxidants International nonproprietary name Ethylmethylhydroxypyridine succinate Composition Action current substance - ethylmethylhydroxypyridine succinate. Manufacturers Moscow Endocrine Plant (Russia) Pharmacological action Nootropic, antioxidant, membrane stabilizing, cerebroprotective, anxiolytic, adaptogenic. Inhibits lipid peroxidation, increases the activity of the antioxidant system, activates the energy-synthesizing functions of mitochondria, improves energy metabolism in the cell, helps maintain the level of macroergs, incl. during stress hypoxia. Activates intracellular synthesis of protein and nucleic acids, enzymatic processes of the Krebs cycle, promotes glucose utilization, synthesis and intracellular accumulation of ATP. Restores the structure and function of membranes, has a modulating effect on membrane-bound enzymes, ion channels, neurotransmitter transport systems, receptor complexes, incl. GABA-benzodiazepine, acetylcholine, improves synaptic transmission and interconnection of brain structures. Improves metabolism and blood supply to the brain, rheological properties of blood and microcirculation, functioning of the immune system, suppresses platelet aggregation. Reduces the level of total cholesterol and LDL and causes regression of atherosclerotic changes in the arteries (hypolipidemic and antiatherogenic effects). It has anti-ischemic properties: improves blood flow, limits the area of ischemic damage and stimulates reparative processes. Increases the body's resistance to the effects of extreme factors and oxygen-dependent pathological conditions, such as shock, stress, sleep deprivation, hypoxia, cerebrovascular accidents, brain injuries, ischemia, electric shock, physical and mental overload, conflict situations, intoxication (ethanol, etc.) . Slows down the aging process. The anti-alcohol effect manifests itself in a sobering effect and weakening of motivation and is used to relieve withdrawal symptoms and treat acute poisoning. Concomitant use with alcohol does not aggravate intoxication, but prevents it. Reduces resistance to psychotropic drugs and enhances their effect, which makes it possible to reduce therapeutic doses and the likelihood of side effects. Radioprotective properties can be used for prophylactic purposes in case of increased radiation levels. Side effects: Allergic reactions, nausea, dry mouth. Indications for use Solution for injection: acute and chronic disorders of cerebral circulation, incl. ischemic stroke and its consequences; dyscirculatory encephalopathy, vegetative-vascular dystonia; psychosomatic diseases; neurotic and neurosis-like disorders with the manifestation of anxiety, fear, emotional stress; memory and attention disorders, impaired mental performance; mental and neurological diseases in old age, cerebral atherosclerosis; relief of alcohol withdrawal syndrome, accompanied by neurosis-like and vegetative-vascular disorders; acute intoxication with neuroleptics; acute purulent-inflammatory processes of the abdominal cavity: acute necrotizing pancreatitis, peritonitis (as part of complex therapy). Tablets (Mexidol, Mexiprim), capsules (Mexicor): coronary heart disease (complex therapy). Contraindications Hypersensitivity to hydroxymethylethylpyridine succinate and/or pyridoxine, acute liver and kidney dysfunction, pregnancy, breastfeeding. There is no sufficient clinical experience of use during pregnancy and lactation. Restrictions on use: Children under 18 years of age (safety and effectiveness of use have not been determined). Overdose In case of overdose, drowsiness is possible. Interaction No data available. Special instructions When working, use with caution for vehicle drivers and people whose profession is associated with increased concentration of attention. Storage conditions List B. Store in a place protected from light.
